Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 9/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28748887 | 0.85 | ADRB3 (0.46) | IDO1ADRB3ADRB1ADRB2ACP3 | |
| SCHEMBL28748861 | 0.85 | ADRB3 (0.46) | IDO1ADRB3ADRB1ADRB2ACP3 | |
| SCHEMBL2329493 | 0.81 | ADRB3 (0.49) | ADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL28748802 | 0.81 | HSD11B1 (0.54) | IDO1ADRB3ADRB1ADRB2ACP3 | |
| SCHEMBL28748821 | 0.81 | HSD11B1 (0.54) | IDO1ADRB3ADRB1ADRB2ACP3 | |
| SCHEMBL768007 | 0.78 | PNMT (0.56) | IDO1ADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL3489554 | 0.78 | PNMT (0.56) | IDO1ADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL31419997 | 0.78 | PNMT (0.56) | IDO1ADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL768162 | 0.78 | PNMT (0.56) | IDO1ADRB3ADRB1ADRB2SLC2A1 | |
| Sulfuric Acid SCHEMBL28213387 | 0.78 | AOC3 (0.47) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302546-A1 | NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) | 2012-11-29 | — | — | US | claimed |
| WO-2011097337-A1 | NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF | ADVANCED NEURAL DYNAMICS, INC. (US) | 2011-08-11 | — | — | WO | claimed |
| US-20120302546-A1 | NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2011097337-A1 | NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF | ADVANCED NEURAL DYNAMICS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302546-A1 | NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF | GRIK2, GRIK5, GRIN2A | IDO1 1465/4885ADRB3 3226/4885ADRB1 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.